Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Dose Vitamin D vs Standard Dose Vitamin D Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01988090
Recruitment Status : Active, not recruiting
First Posted : November 20, 2013
Results First Posted : March 19, 2019
Last Update Posted : March 19, 2019
Sponsor:
Information provided by (Responsible Party):
Mothaffar Rimawi, Baylor Breast Care Center

Brief Summary:
This study is being done to look at the difference, if there is a difference between two different doses of Vitamin D and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications (aromatase inhibitors) by breast cancer patients. The investigators hope to learn if taking a higher dose of Vitamin D is a good way to prevent aromatase inhibitor arthralgia (AIA).

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: 800 IU Vitamin D Supplement Drug: 50,000 IU Vitamin D supplement Phase 2

Detailed Description:
Treatments with anti-estrogen agents for hormone receptor positive breast cancer is the most efficacious of systemic therapies, with aromatase inhibitors (AI's) being considered the most active anti-estrogen therapy in early stage breast cancer. But, use of these treatments has been shown to cause musculoskeletal (joint/muscle) side effects that sometimes cause patients to discontinue the use of them. Also, Vitamin D deficiency is a well know cause of a wide array of musculoskeletal issues. There is evidence that Vitamin D supplementation may help prevent arthralgia while on AI's. Therefore, the investigators want to see if giving a higher dose of Vitamin D could decrease the incidence of AIA as compared to a standard dose of Vitamin D. The investigators believe that this could possibly result in patients continued treatment with AI therapy for hormone receptor positive breast cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors
Study Start Date : December 2013
Actual Primary Completion Date : January 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D

Arm Intervention/treatment
Experimental: High Dose Vitamin D ARM
50,000 IU Vitamin D supplement
Drug: 50,000 IU Vitamin D supplement
High Dose

Active Comparator: 800 IU Vitamin D Supplement
800 IU Vitamin D Supplement
Drug: 800 IU Vitamin D Supplement
Standard Dose




Primary Outcome Measures :
  1. Number of Participants With Aromatase Inhibitor Induced Arthralgia (AIA) After 12 Weeks of Therapy [ Time Frame: 12 weeks ]
    Aromatase Inhibitor Arthralgia (AIA) was assessed by a questionnaire that describe the level of pain experienced by the participant. The questionnaire asks 20 questions scored 0-3 in 8 categories of functioning: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. An average composite score on the HAQ-II was calculated. The visual analog scale is the other major component of the HAQ-II, which we ask patients to mark where their pain lies on a horizontal line and we converts the number into a score from 0 to 3. For the purposes of this study, AIA will be defined as any of the following criteria: 1) increase in HAQ-II score from baseline by 0.2 or greater; or 2) increase in visual analog pain score by 0.3 or greater.


Secondary Outcome Measures :
  1. Compliance With Anti-Cancer Treatment [ Time Frame: 52 Weeks ]
    We checked compliance of aromatase inhibitor therapy during the study by reviewing the patient's use of AI drug. This will be done by counting remaining pills in patient's bottles of AI at 52 weeks. A percentage of the number of pills were actually taken of the number of pills should be taken was calculated.

  2. Association Between Vitamin D Levels Changes and Treatment. [ Time Frame: 12 weeks ]
    Patients' serum 25-hydroxyvitamin D level were tested at baseline and week 12. The changes between baseline and week 12 were calculated.


Other Outcome Measures:
  1. Grip Strength [ Time Frame: 52 weeks ]
    Exploratory Endpoints For each patient on the study, grip strength will be correlated with AIA score using Spearman correlation at three time points throughout the study - baseline, week 12, and week 52.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All participants must be female and at least 21 years of age
  • Signed informed consent
  • Patients must have had histologically confirmed stage I-III breast carcinoma that is positive for Estrogen Receptor (ER) and/or Progesterone Receptor (PR).
  • Post-menopausal
  • Beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks
  • Bisphosphonates are allowed at the treating investigator¡¦s discretion
  • Performance status (WHO/ECOG scale) 0-2.

Exclusion Criteria:

  • History of kidney stones
  • Hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters
  • History of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion
  • Baseline Vitamin D level greater than 50 ng/mL
  • Inability or unwillingness to comply with, or follow study procedures.
  • Currently taking Phenytoin or phenobarbital -7 Currently taking cholestyramine or orlistat
  • Malabsorption syndrome, such as Crohn's disease

Prohibited Therapies: Patients may not take additional Calcium and Vitamin D aside from the study medications. Patients who are on cholestyramine or orlistat will not be allowed on the trial. Also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between Vitamin D and anti-epileptic medications.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01988090


Locations
Layout table for location information
United States, Missouri
Washington University / Siteman Cancer Center
Saint Louis, Missouri, United States, 63110
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Mothaffar Rimawi
Investigators
Layout table for investigator information
Principal Investigator: Mothaffar Rimawi, MD Baylor College of Medicine
  Study Documents (Full-Text)

Documents provided by Mothaffar Rimawi, Baylor Breast Care Center:

Layout table for additonal information
Responsible Party: Mothaffar Rimawi, Professor, Baylor Breast Care Center
ClinicalTrials.gov Identifier: NCT01988090     History of Changes
Other Study ID Numbers: H-33261
First Posted: November 20, 2013    Key Record Dates
Results First Posted: March 19, 2019
Last Update Posted: March 19, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Mothaffar Rimawi, Baylor Breast Care Center:
Breast Cancer
Hormone Receptor Positive
Vitamin D

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Vitamins
Vitamin D
Ergocalciferols
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents